BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 17155856)

  • 1. VEGF/VEGFR signalling as a target for inhibiting angiogenesis.
    Kiselyov A; Balakin KV; Tkachenko SE
    Expert Opin Investig Drugs; 2007 Jan; 16(1):83-107. PubMed ID: 17155856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting VEGF/VEGFR in the treatment of psoriasis.
    Li W; Man XY; Chen JQ; Zhou J; Cai SQ; Zheng M
    Discov Med; 2014 Sep; 18(98):97-104. PubMed ID: 25227750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic agents: an update on small molecule VEGFR inhibitors.
    Schenone S; Bondavalli F; Botta M
    Curr Med Chem; 2007; 14(23):2495-516. PubMed ID: 17979703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
    Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
    Tie J; Desai J
    Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer?
    Raben D; Helfrich B
    Clin Lung Cancer; 2004 Jul; 6(1):48-57. PubMed ID: 15310417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor receptors: expression and function in solid tumors.
    Wey JS; Stoeltzing O; Ellis LM
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):37-45. PubMed ID: 16163158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials.
    Zhang C; Tan C; Ding H; Xin T; Jiang Y
    Curr Pharm Des; 2012; 18(20):2921-35. PubMed ID: 22571661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [VEGF-receptor inhibitors for anti-angiogenesis].
    Shibuya M
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):498-503. PubMed ID: 14639004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
    Tandle A; Libutti SK
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic therapy for high-grade gliomas.
    Chamberlain MC; Raizer J
    CNS Neurol Disord Drug Targets; 2009 Jun; 8(3):184-94. PubMed ID: 19601816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
    Takahashi S
    Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis.
    Shibuya M
    BMB Rep; 2008 Apr; 41(4):278-86. PubMed ID: 18452647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions.
    Takahashi H; Shibuya M
    Clin Sci (Lond); 2005 Sep; 109(3):227-41. PubMed ID: 16104843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
    Hicklin DJ; Ellis LM
    J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future.
    Sharma PS; Sharma R; Tyagi T
    Curr Cancer Drug Targets; 2011 Jun; 11(5):624-53. PubMed ID: 21486218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [VEGF, anti-vEGF and diseases].
    Corvol P
    Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor (VEGF) inhibition--a critical review.
    Moreira IS; Fernandes PA; Ramos MJ
    Anticancer Agents Med Chem; 2007 Mar; 7(2):223-45. PubMed ID: 17348829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.
    Roodhart JM; Langenberg MH; Witteveen E; Voest EE
    Curr Clin Pharmacol; 2008 May; 3(2):132-43. PubMed ID: 18690886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.
    Epstein RJ
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.